Changes in Health State Utility Values in Japanese Patients with End-Stage Breast Cancer

Curr Oncol. 2021 Oct 18;28(5):4203-4212. doi: 10.3390/curroncol28050356.

Abstract

We aimed to determine the dynamic trends in health state utility values (HSUVs) in patients with end-stage breast cancer. We selected 181 patients comprising 137 with primary breast cancer (PBC) and 44 with metastatic breast cancer (MBC) (28 survivors and 16 patients with MBC death). HSUVs were 0.90 and 0.89 in patients with PBC and 0.83 and 0.80 in those with MBC (survivors) at 6 and 3 months, respectively, before the end of the observation period; these values were 0.73 and 0.66, respectively, in those with MBC (deceased) during the aforementioned period. The root-mean-squared error (RMSE) for the decrease in HSUVs over 3 months was 0.10, 0.096, and 0.175 for patients with PBC, MBC (survivors), and MBC (deceased), respectively. One-way analysis of variance for differences in absolute error among the groups was significant (p = 0.0102). Multiple comparisons indicated a difference of 0.068 in absolute error between patients with PBC and those with MBC (deceased) (p = 0.0082). Patients with end-stage breast cancer had well-controlled HSUVs 3 months before death, with a sharp decline in HSUVs in the 3 months leading up to death.

Keywords: HSUV; Japanese patients; breast cancer; clinical oncology; health state utility values.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Breast Neoplasms*
  • Cost-Benefit Analysis
  • Female
  • Humans
  • Japan

Associated data

  • UMIN-CTR/UMIN 000022517